Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. Shares in Novavax almost doubled after Sanofi struck a licensing deal worth up to $1.2bn to commercialise ...
10 de mayo de 2024, 1:08 p. m. ·4 min de lectura Novavax stock (NVAX) skyrocketed on Friday, nearly doubling on the news French drug and vaccine giant Sanofi (SNY) would invest $1.2 billion in a deal ...
Los grupos Sanofi y Novavax, otros rivales en la fabricación de la vacuna contra el Covid-19, sellaron una alianza en este terreno, anunciaron este viernes ambas compañías. Los grupos Sanofi y ...
Novavax shares (NVAX) surged after the vaccine maker said it had struck a licensing deal worth up to $1.4 billion with Sanofi (SNY, FR:SAN). Novavax shares were up 133% in recent trading at $10.11.
LONDON — Novavax, the beleaguered maker of a Covid-19 vaccine, just got a boost of its own. The French pharma company Sanofi on Friday said it had reached a licensing deal to sell Novavax’s ...
(Bloomberg) -- Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Most Read from ...
Novavax Inc. shares surged after the company signed a $1.2 billion licensing agreement with Sanofi that includes commercializing a combined Covid-19 and flu shot. Novavax will receive $500 million in ...
Los grupos Sanofi y Novavax, otrora rivales en la fabricación de la vacuna contra el covid-19, sellaron una alianza en este terreno, anunciaron el viernes ambas compañías. El francés Sanofi ...
En virtud del acuerdo Sanofi adquirirá una participación del 4,9% en la farmacéutica estadounidense. El acuerdo con Taj y la adquisición de participación valoran a Novavax en alrededor de 1. ...
Nueva York, 10 may (EFE).- La biotecnológica estadounidense Novavax se disparaba este viernes un 130 % en Wall Street tras anunciar un acuerdo multimillonario con la farmacéutica francesa Sanofi ...
Política País Negocios Estilo de vida Editorial Mundo Investigación LN pop Impreso Versus Voces Universo GEN Foco:Más Los grupos Sanofi y Novavax, otrora rivales en la fabricación de la ...
Product Sales: $82 million primarily from EP deliveries to Europe Royalties and Other Revenue: $12 million including license fees and Matrix-M reimbursement Cost of Sales (Q1 2024): $59 million R&D ...